NASDAQ:YMAB Y-mAbs Therapeutics (YMAB) Stock Forecast, Price & News $5.22 +0.13 (+2.55%) (As of 09/22/2023 06:55 PM ET) Add Compare Share Share Today's Range$5.07▼$5.2650-Day Range$4.86▼$7.2352-Week Range$2.70▼$15.89Volume116,600 shsAverage Volume420,561 shsMarket Capitalization$227.70 millionP/E RatioN/ADividend YieldN/APrice Target$12.63 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Y-mAbs Therapeutics MarketRank™ ForecastAnalyst RatingHold2.18 Rating ScoreUpside/Downside141.9% Upside$12.63 Price TargetShort InterestBearish7.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.91Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.64) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector604th out of 963 stocksPharmaceutical Preparations Industry281st out of 459 stocks 3.1 Analyst's Opinion Consensus RatingY-mAbs Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 4 buy ratings, 5 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.63, Y-mAbs Therapeutics has a forecasted upside of 141.9% from its current price of $5.22.Amount of Analyst CoverageY-mAbs Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.90% of the float of Y-mAbs Therapeutics has been sold short.Short Interest Ratio / Days to CoverY-mAbs Therapeutics has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Y-mAbs Therapeutics has recently decreased by 17.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldY-mAbs Therapeutics does not currently pay a dividend.Dividend GrowthY-mAbs Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for YMAB. Previous Next 2.7 News and Social Media Coverage News SentimentY-mAbs Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Y-mAbs Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for YMAB on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Y-mAbs Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Y-mAbs Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.50% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.45% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.64) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Y-mAbs Therapeutics is -5.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Y-mAbs Therapeutics is -5.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioY-mAbs Therapeutics has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Y-mAbs Therapeutics (NASDAQ:YMAB) StockY-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.Read More YMAB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart YMAB Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Hold" from AnalystsSeptember 21, 2023 | finance.yahoo.comY-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric OncologySeptember 25, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.September 6, 2023 | finance.yahoo.comY-mAbs to Participate at Upcoming Investor Conferences in SeptemberAugust 23, 2023 | finance.yahoo.comWall Street Analysts Think Y-mAbs Therapeutics, Inc. (YMAB) Could Surge 88.55%: Read This Before Placing a BetAugust 23, 2023 | msn.comJP Morgan Maintains Y-Mabs Therapeutics (YMAB) Underweight RecommendationAugust 14, 2023 | msn.comHC Wainwright & Co. Reiterates Y-Mabs Therapeutics (YMAB) Buy RecommendationAugust 14, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Y-mAbs TherapeuticsSeptember 25, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.August 13, 2023 | finance.yahoo.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | investing.comY mAbs Therapeutics (YMAB) Earnings Dates & ReportsAugust 10, 2023 | finance.yahoo.comY-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsAugust 10, 2023 | finance.yahoo.comY-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue EstimatesAugust 9, 2023 | markets.businessinsider.comY-mAbs Therapeutics earnings: here's what Wall Street expectsAugust 3, 2023 | finance.yahoo.comY-mAbs to Participate at Upcoming Investor ConferencesAugust 1, 2023 | finance.yahoo.comY-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023July 26, 2023 | msn.comCanaccord Genuity Maintains Y-Mabs Therapeutics (YMAB) Buy RecommendationJuly 26, 2023 | finance.yahoo.comInstitutional owners may take dramatic actions as Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent 13% drop adds to one-year lossesJuly 25, 2023 | markets.businessinsider.comAnalyst Expectations for Y-mAbs Therapeutics's FutureJuly 25, 2023 | msn.comY-mAbs Therapeutics: Interesting History But Questions AboundJune 8, 2023 | msn.comCanaccord Genuity Reiterates Y-Mabs Therapeutics (YMAB) Buy RecommendationJune 7, 2023 | markets.businessinsider.comCanaccord Genuity Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)June 2, 2023 | finance.yahoo.comY-mAbs Therapeutics (NASDAQ:YMAB investor three-year losses grow to 81% as the stock sheds US$53m this past weekMay 26, 2023 | finance.yahoo.comY-mAbs Announces Presentation of GD2-SADA Study at ASCOMay 26, 2023 | finance.yahoo.comY-mAbs Announces Presentation of Naxitamab Data at ASCOMay 23, 2023 | finance.yahoo.comY-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in BrazilMay 15, 2023 | msn.comB of A Securities Maintains Y-Mabs Therapeutics (YMAB) Neutral RecommendationSee More Headlines Receive YMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address YMAB Company Calendar Last Earnings8/10/2023Today9/25/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:YMAB CUSIPN/A CIK1722964 Webwww.ymabs.com Phone(646) 885-8505FaxN/AEmployees147Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.63 High Stock Price Forecast$22.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+141.9%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,570,000.00 Net Margins-45.96% Pretax Margin-45.75% Return on Equity-36.37% Return on Assets-28.14% Debt Debt-to-Equity RatioN/A Current Ratio4.78 Quick Ratio4.56 Sales & Book Value Annual Sales$84.99 million Price / Sales2.68 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book2.09Miscellaneous Outstanding Shares43,620,000Free Float34,242,000Market Cap$227.70 million OptionableNot Optionable Beta0.71 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Thomas Gad (Age 53)Founder, Interim CEO, Pres, Head of Bus. Devel. & Strategy and Director Comp: $1.05MMr. Bo Kruse (Age 51)Exec. VP, Sec., Treasurer & CFO Comp: $685.02kMs. Susan Smith (Age 52)Sr. VP & Chief Commercial Officer Comp: $710kMr. Joris Wiel Jan Wilms (Age 49)Sr. VP & COO Dr. Torben Lund-Hansen M.Sc. (Age 72)Ph.D., Sr. VP & CTO Dr. Steen Lisby M.D. (Age 59)M.Sc., Sr. VP & Chief Scientific Officer Dr. Vignesh Rajah M.B.A. (Age 58)MBBS, Sr. VP & Chief Medical Officer More ExecutivesKey CompetitorsAcrivon TherapeuticsNASDAQ:ACRVAstria TherapeuticsNASDAQ:ATXSAkebia TherapeuticsNASDAQ:AKBAImmuneeringNASDAQ:IMRXGossamer BioNASDAQ:GOSSView All CompetitorsInsiders & InstitutionsBarclays PLCSold 40,092 shares on 9/21/2023Ownership: 0.017%Nuveen Asset Management LLCBought 91,439 shares on 8/16/2023Ownership: 0.974%Alliancebernstein L.P.Bought 11,350 shares on 8/15/2023Ownership: 0.383%Wells Fargo & Company MNBought 7,549 shares on 8/15/2023Ownership: 0.034%Citadel Advisors LLCBought 1,200 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions YMAB Stock - Frequently Asked Questions Should I buy or sell Y-mAbs Therapeutics stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares. View YMAB analyst ratings or view top-rated stocks. What is Y-mAbs Therapeutics' stock price forecast for 2023? 11 Wall Street research analysts have issued 12 month price targets for Y-mAbs Therapeutics' shares. Their YMAB share price forecasts range from $5.00 to $22.00. On average, they expect the company's stock price to reach $12.63 in the next twelve months. This suggests a possible upside of 141.9% from the stock's current price. View analysts price targets for YMAB or view top-rated stocks among Wall Street analysts. How have YMAB shares performed in 2023? Y-mAbs Therapeutics' stock was trading at $4.88 at the start of the year. Since then, YMAB shares have increased by 7.0% and is now trading at $5.22. View the best growth stocks for 2023 here. When is Y-mAbs Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our YMAB earnings forecast. How were Y-mAbs Therapeutics' earnings last quarter? Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.10. The firm earned $20.75 million during the quarter, compared to analyst estimates of $19.04 million. Y-mAbs Therapeutics had a negative net margin of 45.96% and a negative trailing twelve-month return on equity of 36.37%. What guidance has Y-mAbs Therapeutics issued on next quarter's earnings? Y-mAbs Therapeutics issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80.00 million-$85.00 million, compared to the consensus revenue estimate of $82.79 million. What other stocks do shareholders of Y-mAbs Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN). When did Y-mAbs Therapeutics IPO? (YMAB) raised $80 million in an initial public offering on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager. What is Y-mAbs Therapeutics' stock symbol? Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB." Who are Y-mAbs Therapeutics' major shareholders? Y-mAbs Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.80%), Polar Capital Holdings Plc (4.82%), State Street Corp (1.71%), Geode Capital Management LLC (1.63%), Acadian Asset Management LLC (1.50%) and Nuveen Asset Management LLC (0.97%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah. View institutional ownership trends. How do I buy shares of Y-mAbs Therapeutics? Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Y-mAbs Therapeutics' stock price today? One share of YMAB stock can currently be purchased for approximately $5.22. How much money does Y-mAbs Therapeutics make? Y-mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $227.70 million and generates $84.99 million in revenue each year. The company earns $-95,570,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. How many employees does Y-mAbs Therapeutics have? The company employs 147 workers across the globe. How can I contact Y-mAbs Therapeutics? Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The official website for the company is www.ymabs.com. The company can be reached via phone at (646) 885-8505 or via email at info@ymabs.com. This page (NASDAQ:YMAB) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.